More: Advances in Ulcerative Colitis

Advances in Ulcerative Colitis - Volume 4 CME

Author Information and Disclosures

Release Date: March 28, 2008Valid for credit through March 28, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s) for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

  1. Long-term Maintenance of Remission in Ulcerative ColitisWilliam Sandborn, MD, reviews the data on maintenance therapy for ulcerative colitis, which is indicated to prevent symptomatic and endoscopic relapse and to minimize the risk for colectomy and CRC.
  2. Quality of Life in Ulcerative ColitisDavid Limsui, MD, and Darrell Pardi, MD, explore the impact of UC on HR-QOL, a standard measure of the quality of care from a patient's viewpoint and an important outcome measure in clinical trials.
  3. Literature Review - Surgical Intervention in Ulcerative ColitisBret A. Lashner, MD, provides clinical commentary for select feature articles from the literature on the role of surgery in ulcerative colitis; this is followed by a new serial learning outcomes study.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.


Shire

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the latest data on medical therapies shown to be effective for maintenance of remission in ulcerative colitis, including 5-aminosalicylic acid (5-ASA)-containing medications, azathioprine, and infliximab
  2. Discuss the impact of ulcerative colitis on health-related quality of life, including comparison with the general population and other chronic diseases as well as the effect of therapeutic intervention
  3. Review the latest data regarding the role of surgery in the setting of ulcerative colitis, as reflected in the recent literature
Authors and Disclosures

William J. Sandborn, MD
Disclosure: William J. Sandborn, MD, has disclosed that he has received grants for clinical research from, and has served as an advisor or consultant to, Shire Pharmaceuticals and Procter & Gamble Pharmaceuticals. Dr. Sandborn has also disclosed that he has served as a consultant to Salix Pharmaceuticals.


Darrell S. Pardi, MD
Disclosure: Darrell S. Pardi, MD, has disclosed that he has received grants for clinical research from AstraZeneca, Proctor & Gamble, and Salix. Dr. Pardi has also disclosed that he has served as an advisor or consultant to Salix.


David Limsui, MD
Disclosure: David Limsui, MD, has disclosed no relevant financial relationships.


Bret A. Lashner, MD
Disclosure: Bret A. Lashner, MD, has disclosed that he has served as an advisor or consultant to Shire, Elan, Abbott, UCB, Prometheus, and Procter & Gamble.


Maria Gaiso
Disclosure: Maria Gaiso has disclosed no relevant financial relationships.


 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.